The outcome of TCR stimulation is regulated by the simultaneous engagement of the costimulatory molecule CD28. Mice lacking CD28 can still mount T cell responses but require repeated stimulations with high doses of antigen (1) . In vitro studies demonstrated that in the absence of CD28 engagement, T cells require a very high TCR occupancy and a prolonged stimulation, whereas when costimulated through CD28 they respond more rapidly to lower levels of TCR occupancy (2, 3) . Although CD28 can specifically enhance distinct signaling pathways leading to gene transcription (4) (5) (6) , the mechanism by which CD28 facilitates T cell activation remains elusive. One possibility is that CD28 might exert its costimulatory action by acting as a general amplifier of early TCR signaling.
To study the mechanism of CD28 costimulation, we stimulated human resting T cells with surrogate antigen-presenting cells (APCs), consisting of beads coated with various concentrations of antibody to CD3 (anti-CD3) in the presence or absence of anti-CD28 (7) . Resting T cells proliferated in response to beads coated with anti-CD3 plus anti-CD28, but not to beads coated with anti-CD3 alone (Fig. 1A ). An enhancing effect of CD28 engagement was also evident when early tyrosine phosphorylation events were measured. Stimulation of resting T cells with anti-CD3-plus anti-CD28 -coated beads induced more tyrosine phosphorylation on multiple proteins and, as compared with beads coated with anti-CD3 alone, shifted the dose-response curve to at least 10-fold lower levels of anti-CD3 (Fig. 1B) . The different responses did not reflect different numbers of TCR triggering events because the same number of TCR-CD3 complexes was down-regulated in the absence or presence of costimulation (Fig. 1C) . These results confirm previous experiments showing that engagement of CD28 increases the T cell response (2) as well as early tyrosine phosphorylation (8) and show that this effect is not due to higher numbers of TCRs triggered. To explain this paradox we considered the possibility that the increased tyrosine phosphorylation observed when CD28 was engaged might be due to the presence of phosphorylated molecules for a longer time.
To fully activate T cells, antigen-stimulated TCR signaling needs to be sustained for up to several hours (9) , which requires ongoing TCR triggering. As soon as the serial triggering process is blocked, signaling, as measured by Ca 2ϩ increases or acid production, is terminated within minutes (10) . To measure the lifespan of phosphorylation induced by TCR triggering, we stimulated T cells with beads and analyzed tyrosine phosphorylation before and at various times after the addition of the powerful tyrosine kinase inhibitor {4-amino-5-(4-methyphenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine} (PP1) (11) . In the absence of costimulation through CD28, all the tyrosine-phosphorylated substrates disappeared rapidly after the addition of PP1 and were undetectable within less than 30 s. In contrast, when costimulation was provided, tyrosine phosphorylation was more persistent because it was still detectable after 2 min ( Fig. 2A ). This increased stability was observed for all of the most prominent tyrosine-phosphorylated substrates including LAT, an adapter molecule that links TCR to downstream effectors (12, 13) . In addition, CD28 engagement resulted in increased degradation of Lck (Fig. 2B) , indicating that more kinase is recruited and consumed by the same number of triggered TCRs.
The above results show that tyrosine phosphorylation, which is rapidly induced after TCR engagement (14) , is very transient because it is rapidly lost as soon as kinases are inhibited. CD28, rather than acting on a distinct pathway, acts early on by enhancing global aspects of TCR signaling. Costimulation results in higher steady-state levels of phosphorylation because of increased recruitment of Lck and increased stability of phosphorylation, possibly as a result of lower activity or accessibility of phosphatases.
To explain how CD28 might globally increase TCR-induced Lck consumption and substrate phosphorylation, we considered the possibility that CD28 induces a reorganization of the signaling machinery. The plasma membrane is composed of discrete lipid microdomains in which membrane molecules are differentially partitioned (15) . These sphingolipid-cholesterol-rich rafts concentrate glycophosphatidylinositol-linked proteins, glycosphingolipids, as well as several molecules involved in signal transduction such as Lck, LAT, Ras, and guanosine triphosphate-binding proteins (G proteins) (16 ) . In polarized cells rafts are concentrated at the apical surface, whereas in nonpolarized cells they are dispersed over the cell surface as small domains of Ͻ70 nm (17) . We tested whether CD28 engagement affects the distribution of rafts using as a raft marker fluorescein isothiocyanate (FITC)-labeled cholera toxin (CTx) B subunit, which binds the GM1 glycosphingolipid (18) (Fig. 3, A to C) . In unstimulated resting T lymphocytes the surface distribution of GM1 appeared homogeneous, and this pattern did not change when the cells were stimulated with anti-CD3-coated beads. By contrast, when CD3 and CD28 were simultanously engaged, within 15 min GM1 had redistributed to form a dense cap that contacted the stimulating bead, indicating that rafts had aggregated in the zone of contact. A time-dependent increase in CTx binding was measured by flow cytometric analysis in T cells conjugated with anti-CD3 plus anti-CD28 beads (Fig. 3D) . Whereas in effector T cells GM1 was present at high levels only on the cell surface, in resting T cells it was mainly intracellular and was present only at low levels on the cell surface (Fig. 3E) .
The above results indicate that CD28 engagement promotes redistribution of rafts at the TCR contact site, a process that may amplify and sustain TCR-induced signaling by segregating strategically important molecules. We therefore asked whether passive clustering of rafts and triggered TCRs would provide costimulation to resting T cells (19) . Both CTx or a monoclonal antibody to the GPI-anchored protein CD59 provided efficient costimulation when immobilized on culture wells together with anti-CD3 (Fig. 4A) . However, when presented on anti-CD3-coated beads, no costimulatory effects were observed (Fig. 4B) . These results suggest that passive aggregation of rafts by cross-linking of rafts-associated molecules can provide effective costimulation under the favorable conditions afforded by a large surface area of interaction. However, under less favorable conditions provided by the beads, GM1 and CD59, in contrast to CD28, failed to reorganize rafts into an active configuration. Indeed, GM1 was not redistributed in T cells stimulated by anti-CD3-plus anti-CD59 -coated beads (13) .
Kupfer et al. have shown that T cells polarize toward the APCs, thereby forming a highly structured synapse. This process involves rearrangements of the T cell's cytoskeleton as well as redistribution of surface molecules. Some molecules, such as TCR, CD4, CD2, and CD28, are enriched in a central zone, whereas others, such as LFA-1 and CD45, remain outside (20) . TCR triggering leads to T cell polarization (21) and to a redistribution of membrane molecules that is mediated by CD2 (22). Our results are consistent with this model, but in addition demonstrate that ongoing TCR triggering is required to sustain the signaling process. We have shown here that CD28 participates in the organization of the immune synapse by recruiting rafts into it (23) . The fact that crosslinking of the rafts produced levels of costimulation comparable to that of CD28 engagement suggests that the costimulatory effect of CD28 in resting T cells is mediated to a large extent by its effect on raft redistribution.
Recent evidence suggests that membrane compartmentalization between rafts and nonrafts is required for efficient T cell activation (24) . The recruitment of rafts to the site of TCR engagement may represent a general mechanism by which costimulation can increase the signaling process. This may result from increased recruitment of kinases and segregation of phosphorylated substrates from phosphatases (25) . Human HSCs are an attractive target for gene therapy of inherited hematopoietic disorders as well as other acquired disorders because these cells have the ability to regenerate the entire hematopoietic system. A number of in vitro assays have been established to detect pluripotent human hematopoietic cells (1) . However, these in vitro assays are unable to evaluate the long-term in vivo repopulating capacity that is a hallmark of HSCs. The NOD/SCID mouse (2) has been used to evaluate human HSCs in vivo (3). CD34
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